XERIS BIOPHARMA HOLDINGS, INC. (XERS) FY2026 YTD Q2 Statement of Cash Flows

Income StatementCash FlowBalance Sheet

Statement of Cash Flows

2026-01-01 to 2026-06-30

Swipe to see the full flow
XERIS BIOPHARMA HOLDINGS, INC. cash flow reconciliation, Jan 1, 2026 through Jun 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Read chart description and values below for full signed amounts, including zero items.Loss on debt extinguishment, net → operating reconciliation: $30,782,000.00Stock-based compensation → operating reconciliation: $15,206,000.00Accrued trade discounts and rebates → operating reconciliation: $12,305,000.00Amortization of intangible assets → operating reconciliation: $5,421,000.00Accounts payable → operating reconciliation: $4,536,000.00Amortization of debt discount and debt issuance costs → operating reconciliation: $1,796,000.00Depreciation → operating reconciliation: $660,000.00Amortization of operating right-of-use assets → operating reconciliation: $339,000.00Other → operating reconciliation: $296,000.00operating reconciliation → Net cash from operating activities: $18,133,000.00operating reconciliation → Net loss: $28,867,000.00operating reconciliation → Inventory: $8,651,000.00operating reconciliation → Trade accounts receivable: $7,055,000.00operating reconciliation → Prepaid expenses and other current assets: $4,344,000.00operating reconciliation → Other accrued liabilities: $3,009,000.00operating reconciliation → Operating lease liabilities: $911,000.00operating reconciliation → Accrued returns reserve: $371,000.00Net cash used in investing activities → investing reconciliation: $534,000.00investing reconciliation → Capital expenditures: $534,000.00Net cash used in financing activities → financing reconciliation: $6,894,000.00Proceeds from Issuance of Warrants → financing reconciliation: $7,933,000.00Proceeds from exercise of stock options → financing reconciliation: $1,396,000.00Proceeds from issuance of employee stock purchase plan shares → financing reconciliation: $985,000.00financing reconciliation → Repurchase of common stock withheld for taxes: $17,208,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $115,063,000.00Net cash from operating activities → Cash sources and uses: $18,133,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $125,768,000.00Cash sources and uses → Net cash used in investing activities: $534,000.00Cash sources and uses → Net cash used in financing activities: $6,894,000.00Net loss: -$28,867,000.00Net loss−$28.87 MDepreciation: $660,000.00Depreciation & amortization+$660.00 KAmortization of intangible assets: $5,421,000.00Intangible amortization+$5.42 MAmortization of debt discount and debt issuance costs: $1,796,000.00Debt issuance cost amortization+$1.80 MAmortization of operating right-of-use assets: $339,000.00Operating lease amortization+$339.00 KStock-based compensation: $15,206,000.00Stock-based compensation+$15.21 MTrade accounts receivable: -$7,055,000.00Accounts receivable−$7.06 MPrepaid expenses and other current assets: -$4,344,000.00Prepaid expenses−$4.34 MInventory: -$8,651,000.00Inventories−$8.65 MAccounts payable: $4,536,000.00Accounts payable+$4.54 MOther accrued liabilities: -$3,009,000.00Accrued liabilities−$3.01 MAccrued trade discounts and rebates: $12,305,000.00Accrued trade discounts & rebates+$12.31 MAccrued returns reserve: -$371,000.00Accrued returns reserve−$371.00 KOperating lease liabilities: -$911,000.00Operating lease liabilities−$911.00 KOther: $296,000.00Other operating liabilities+$296.00 KLoss on debt extinguishment, net: $30,782,000.00Debt extinguishment gain & loss+$30.78 MNet cash from operating activities: $18,133,000.00Operating cash+$18.13 Moperating reconciliation: $71,341,000.00Proceeds from exercise of stock options: $1,396,000.00Stock option exercises+$1.40 MProceeds from Issuance of Warrants: $7,933,000.00Warrants issued+$7.93 MRepurchase of common stock withheld for taxes: -$17,208,000.00Stock-award tax withholding−$17.21 MProceeds from issuance of employee stock purchase plan shares: $985,000.00Stock plan proceeds+$985.00 KNet cash used in financing activities: -$6,894,000.00. Cash required to fund net payments.Financing cash−$6.89 Mfinancing reconciliation: $17,208,000.00Capital expenditures: -$534,000.00Capital expenditures−$534.00 KNet cash used in investing activities: -$534,000.00. Cash required to fund net payments.Investing cash−$534.00 Kinvesting reconciliation: $534,000.00Cash sources and uses: $133,196,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $115,063,000.00Beginning cash$115.06 MEnding cash: Cash, cash equivalents, and restricted cash: $125,768,000.00Ending cash$125.77 MCASH RECONCILIATIONOperatingflowsInvestingflowsFinancingflowsNet loss −$28.87M + net operating adjustments $47.00M = operating cash +$18.13MFree cash flowNot availableCash flow / Net incomeNot meaningfulOperating cash flow ÷ net incomeNet cash change+$10.71 MEnding cash − beginning cash
Chart details

XERIS BIOPHARMA HOLDINGS, INC. cash flow reconciliation, Jan 1, 2026 through Jun 30, 2026

Cash flows for Jan 1, 2026 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Dec 31, 2025. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Dec 31, 2025
115,063,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
18,133,000 US dollars. Net cash provided.
Net loss
negative 28,867,000 US dollars
Depreciation
660,000 US dollars
Amortization of intangible assets
5,421,000 US dollars
Amortization of debt discount and debt issuance costs
1,796,000 US dollars
Amortization of operating right-of-use assets
339,000 US dollars
Stock-based compensation
15,206,000 US dollars
Trade accounts receivable
negative 7,055,000 US dollars
Prepaid expenses and other current assets
negative 4,344,000 US dollars
Inventory
negative 8,651,000 US dollars
Accounts payable
4,536,000 US dollars
Other accrued liabilities
negative 3,009,000 US dollars
Accrued trade discounts and rebates
12,305,000 US dollars
Accrued returns reserve
negative 371,000 US dollars
Operating lease liabilities
negative 911,000 US dollars
Other
296,000 US dollars
Loss on debt extinguishment, net
30,782,000 US dollars
Investing activities
negative 534,000 US dollars. Net cash used.
Capital expenditures
negative 534,000 US dollars
Financing activities
negative 6,894,000 US dollars. Net cash used.
Proceeds from exercise of stock options
1,396,000 US dollars
Proceeds from Issuance of Warrants
7,933,000 US dollars
Repurchase of common stock withheld for taxes
negative 17,208,000 US dollars
Proceeds from issuance of employee stock purchase plan shares
985,000 US dollars
Operating adjustment reconciliation
71,341,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
17,208,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
534,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
0 US dollars
Ending cash on Jun 30, 2026
125,768,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
133,196,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
10,705,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
Not meaningful. Operating cash flow divided by reconciliation net income for the same period. The ratio is not meaningful when net income is zero or negative.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net loss −$28.87M + net operating adjustments $47.00M = operating cash +$18.13M. The loss reduces the earnings basis of the reconciliation; it is not a cash payment. The signed loss remains a deduction at the operating reconciliation junction.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
XERIS BIOPHARMA HOLDINGS, INC. (XERS) FY2026 YTD Q2 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!